Transcranial Photobiomodulation Therapy as an Intervention for Opioid Cravings and Depression: A Pilot Cohort Study.

IF 1.8 Q2 SURGERY
Jennifer Flora, Kelly Watson Huffer
{"title":"Transcranial Photobiomodulation Therapy as an Intervention for Opioid Cravings and Depression: A Pilot Cohort Study.","authors":"Jennifer Flora, Kelly Watson Huffer","doi":"10.1089/photob.2024.0032","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> The opioid crisis, a declared national health emergency, has prompted the exploration of innovative treatments to address the pervasive issues of opioid cravings and associated depression. <b><i>Aims:</i></b> This pilot cohort study investigated the efficacy of transcranial Photobiomodulation (tPBM) therapy using the SunPowerLED helmet to alleviate these symptoms in individuals undergoing treatment for opioid addiction at a rehabilitation center in West Virginia. <b><i>Methods:</i></b> Employing a quasi-experimental design, this study enrolled participants into two groups: one receiving tPBM therapy alongside standard care and a control group receiving standard care alone. The helmet features include the following: total wavelength = 810 nm, total irradiance = 0.06 W/cm<sup>2</sup> (60 m W/cm<sup>2</sup>), and total fluence = 172.8J/cm<sup>2</sup>. <b><i>Results:</i></b> The results of the Wilcoxon signed-rank tests for within-group analysis and Mann-Whitney U tests for between-group comparisons revealed statistically significant reductions in the intensity (W = 7.36<i>, p</i> = 0.012), time (W = 6.50, <i>p</i> = 0.015), frequency (W = 6.50, <i>p</i> = 0.010), and total scores of opioid cravings (W = 7.50, <i>p</i> = 0.009), as well as improvements in depression symptoms (W= 8.00, <i>p</i> = 0.005) within the PBM group compared to the non-PBM group. <b><i>Discussion:</i></b> These findings suggest that transcranial PBM therapy could be a promising noninvasive intervention for reducing opioid cravings and depressive symptoms in individuals with opioid use disorder, warranting further investigation through larger randomized controlled trials.</p>","PeriodicalId":94169,"journal":{"name":"Photobiomodulation, photomedicine, and laser surgery","volume":" ","pages":"509-513"},"PeriodicalIF":1.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photobiomodulation, photomedicine, and laser surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/photob.2024.0032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The opioid crisis, a declared national health emergency, has prompted the exploration of innovative treatments to address the pervasive issues of opioid cravings and associated depression. Aims: This pilot cohort study investigated the efficacy of transcranial Photobiomodulation (tPBM) therapy using the SunPowerLED helmet to alleviate these symptoms in individuals undergoing treatment for opioid addiction at a rehabilitation center in West Virginia. Methods: Employing a quasi-experimental design, this study enrolled participants into two groups: one receiving tPBM therapy alongside standard care and a control group receiving standard care alone. The helmet features include the following: total wavelength = 810 nm, total irradiance = 0.06 W/cm2 (60 m W/cm2), and total fluence = 172.8J/cm2. Results: The results of the Wilcoxon signed-rank tests for within-group analysis and Mann-Whitney U tests for between-group comparisons revealed statistically significant reductions in the intensity (W = 7.36, p = 0.012), time (W = 6.50, p = 0.015), frequency (W = 6.50, p = 0.010), and total scores of opioid cravings (W = 7.50, p = 0.009), as well as improvements in depression symptoms (W= 8.00, p = 0.005) within the PBM group compared to the non-PBM group. Discussion: These findings suggest that transcranial PBM therapy could be a promising noninvasive intervention for reducing opioid cravings and depressive symptoms in individuals with opioid use disorder, warranting further investigation through larger randomized controlled trials.

经颅光生物调节疗法作为阿片类药物渴求和抑郁的干预措施:一项试点队列研究
简介阿片类药物危机已被宣布为国家健康紧急状况,这促使人们探索创新疗法,以解决阿片类药物渴求和相关抑郁等普遍问题。目的:这项试验性队列研究调查了使用 SunPowerLED 头盔进行经颅光生物调制疗法(tPBM)的疗效,以减轻在西弗吉尼亚州一家康复中心接受阿片类药物成瘾治疗的患者的这些症状。方法:本研究采用准实验设计,将参与者分为两组:一组在接受标准治疗的同时接受 tPBM 治疗,另一组则只接受标准治疗。头盔特点如下:总波长 = 810 纳米,总辐照度 = 0.06 W/cm2 (60 m W/cm2),总通量 = 172.8J/cm2。结果组内分析的 Wilcoxon 符号秩检验和组间比较的 Mann-Whitney U 检验结果显示,强度(W = 7.36,p = 0.012)、时间(W = 6.50,p = 0.015)、频率(W = 6.50,p = 0.010)和阿片类药物渴求的总分(W = 7.50,p = 0.009),以及与非 PBM 组相比,PBM 组的抑郁症状(W = 8.00,p = 0.005)有所改善。讨论这些研究结果表明,经颅PBM疗法可能是减少阿片类药物使用障碍患者阿片类药物渴求和抑郁症状的一种很有前景的非侵入性干预措施,值得通过更大规模的随机对照试验进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
0
期刊介绍: Photobiomodulation, Photomedicine, and Laser Surgery Editor-in-Chief: Michael R Hamblin, PhD Co-Editor-in-Chief: Heidi Abrahamse, PhD
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信